[Evaluation of the efficacy of a new antimycotic molecule for topical use: naftifine].
The antifungal efficacy and tolerability of naftifine (cream, gel, 1% solution), were tested in an open, mycologically controlled study in 29 patients (mean age 32.7 +/- 2.8 years; 15 males, 14 females) with dermatomycosis caused by dermatophytes and yeasts. Particularly, 16 patients were affected with Tinea corporis; 11 patients by Pityriasis Versicolor and 2 other by cutaneous candidiasis. The mean treatment period was 32.9 days in a range from 1 to 44 days. Only one patient, with cutaneous candidiasis dropped out on the first day, because of a primary irritative dermatitis. All the remaining patients (96.4%) were recovered, and the severity of clinical symptoms, particularly erythema and itching, showed a very rapid decline. Two weeks after the treatment, a relapse emerged from a fungal growth culture, only in 2 patients (6.8%) affected with Microsporum canis. Local side effects, mostly burning, were recorded in 2 patients (6.8%).
Albanese
G
G
Giorgetti
P
P
Santagostino
L
L
Di Cintio
R
R
Colombo
M D
MD
D000328:Adult; D000499:Allylamine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000588:Amines / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003881:Dermatomycoses / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D009824:Ointments; D012996:Solutions
D000588:Amines; D000935:Antifungal Agents; D005782:Gels; D009824:Ointments; D012996:Solutions; D000499:Allylamine; C029178:naftifine
Valutazione dell'efficacia di una nuova molecola antimicotica per uso topico: la naftifina.